Novartis announced disappointing sales for a key psoriasis drug and the looming retirement of its respected finance chief, which overshadowed a modest outlook raise. Novartis CEO Vasant Narasimham speaks with Bloomberg's Scarlet Fu on the impact of pharma tariffs.
See omnystudio.com/listener for privacy information.